Bioptix appoints Michael Beeghley new CEO

Bioptix appoints Michael Beeghley new CEO

CASTLE ROCK -- Bioptix, Inc. (Nasdaq: BIOP) announced its board of directors has appointed Michael M. Beeghley as CEO effective April 6, 2017. Beeghley succeeds Steve Lundy , who resigned... Read More

Wednesday April 12, 2017 0 comments Tags: Castle Rock, BiOptix, Michael Beeghley, Steve Lundy

Venaxis changes name to Bioptix, symbol to BIOP

Venaxis changes name to Bioptix, symbol to BIOP

BOULDER --Venaxis Inc. (Nasdaq: APPY), announced it is changing the companys name to Bioptix Inc . following approval from shareholders at the 2016 annual meeting of shareholders. The... Read More

Monday December 12, 2016 0 comments Tags: Boulder, Venaxis, BiOptix, Steve Lundy, APPY, BIOP

Venaxis announces acquisition of BiOptix

Venaxis announces acquisition of BiOptix

CASTLE ROCK -- Venaxis Inc. (Nasdaq: APPY), today announced it has acquired Boulder-based BiOptix Diagnostics, Inc. ("BiOptix"), a privately held company. Venaxis has developed a proprietary... Read More

Wednesday September 14, 2016 0 comments Tags: Venaxis, Castle Rock, Boulder, BiOptix, Surface Plasmon Resonance, Steve Lundy

Venaxis closes public stock offering, raises $14.4 million for APPY1

Venaxis closes public stock offering, raises $14.4 million for APPY1

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY) announced it has closed its underwritten public offering that resulted in the sale of 11.5 million shares of common stock and gross proceeds of $14.4... Read More

By: Steve Friday May 31, 2013 0 comments Tags: APPY1, Castle Rock, Steve Lundy, Venaxis

Venaxis obtains CE Mark for APPY1 appendicitis test

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY), an in-vitro diagnostic company, has fulfilled the requirements for CE Marking in Europe for its APPY1 blood-based appendicitis test, the company announced.... Read More

By: Steve Tuesday January 8, 2013 0 comments Tags: APPY1, Castle Rock, CE Mark, Steve Lundy, Venaxis

AspenBio Pharma changes its name to Venaxis

AspenBio Pharma changes its name to Venaxis

CASTLE ROCK - Venaxis Inc. (Nasdaq: APPY) - formerly AspenBio Pharma - has changed its corporate name after a recent meeting of its shareholders, the company announced. The company's... Read More

By: Steve Friday December 14, 2012 0 comments Tags: AspenBio Pharma, Castle Rock, Steve Lundy, Venaxis

AspenBio Pharma seeks name change to Vanaxis

AspenBio Pharma seeks name change to Vanaxis

CASTLE ROCK - AspenBio Pharma Inc. (Nasdaq: APPY) will ask its stockholders to approve changing its name to Vanaxis Inc., the company announced. AspenBio, an in vitro diagnostic company,... Read More

By: Steve Wednesday October 17, 2012 0 comments Tags: AspenBio Pharma, Castle Rock, Steve Lundy, Vanaxis

AspenBio Pharma adds industry veteran to lead AppyScore product development

AspenBio Pharma adds industry veteran to lead AppyScore product development

CASTLE ROCK - AspenBio Pharma Inc. (Nasdaq: APPY) has added medical diagnostic and biotechnology veteran Dr. Lyndal Hesterberg to lead the company's AppyScore product development, the company... Read More

By: Steve Friday August 3, 2012 0 comments Tags: AppyScore, AspenBio Pharma, Steve Lundy